Extensive stage small cell lung cancer: determining suitability for outpatient management of febrile neutropenia.
Rapp
J S
JS
Division of Infectious Diseases, Thomas Jefferson University, Philadelphia, PA, USA.
Perry
M C
MC
Rotche
R M
RM
D000310:Adrenal Gland Neoplasms / Q000556:secondary; D000553:Ambulatory Care; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D018288:Carcinoma, Small Cell / Q000188:drug therapy* / Q000556:secondary; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003657:Decision Making; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D005334:Fever / Q000628:therapy*; D006760:Hospitalization; D006801:Humans; D008113:Liver Neoplasms / Q000556:secondary; D008175:Lung Neoplasms / Q000188:drug therapy*; D008875:Middle Aged; D009503:Neutropenia / Q000628:therapy*
D000900:Anti-Bacterial Agents; D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D005047:Etoposide; D002945:Cisplatin